A Study of QLM2011 in Subjects With Advanced Solid Tumors
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: QLM2011|DRUG: TaxotereÂ®
Dose-limiting toxicity (DLT), The DLT of QLM2011 will be determined., 21 days|Maximum tolerated dose (MTD), The maximum tolerated dose (MTD) (if available) of QLM2011., up to 1 years|recommended Phase 2 dose (RP2D), recommended Phase 2 dose (RP2D) of QLM2011., up to 1 years
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.